Log-in / Create Account  
 
DIA 48th Annual Meeting
Click here to go to the previous page
Risk Evaluation and Mitigation Strategy (REMS): 18-Month Assessment Report of Dalfampridine Extended Release 10 mg Tablets
Track : Professional Poster Session 1, Tuesday June 26, 2012
Program Code: T01
PRESENTER :
Calvin Mai, Acorda Therapeutics, Inc., United States

Handout Online
(Code: T01)
Attendee:
Attendees Login